202 related articles for article (PubMed ID: 29373929)
1. Third-Generation Human Epidermal Growth Factor Receptor 2 Chimeric Antigen Receptor Expression on Human T Cells Improves with Two-Signal Activation.
Dalal AR; Homsy S; Balkhi MY
Hum Gene Ther; 2018 Aug; 29(8):845-852. PubMed ID: 29373929
[TBL] [Abstract][Full Text] [Related]
2. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
[TBL] [Abstract][Full Text] [Related]
3. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
4. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model.
Festag MM; Festag J; Fräßle SP; Asen T; Sacherl J; Schreiber S; Mück-Häusl MA; Busch DH; Wisskirchen K; Protzer U
Mol Ther; 2019 May; 27(5):947-959. PubMed ID: 30852138
[TBL] [Abstract][Full Text] [Related]
6. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
Gargett T; Brown MP
Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
[TBL] [Abstract][Full Text] [Related]
7. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
[TBL] [Abstract][Full Text] [Related]
8. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies.
Kalamasz D; Long SA; Taniguchi R; Buckner JH; Berenson RJ; Bonyhadi M
J Immunother; 2004; 27(5):405-18. PubMed ID: 15314550
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
10. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity.
Helsen CW; Hammill JA; Lau VWC; Mwawasi KA; Afsahi A; Bezverbnaya K; Newhook L; Hayes DL; Aarts C; Bojovic B; Denisova GF; Kwiecien JM; Brain I; Derocher H; Milne K; Nelson BH; Bramson JL
Nat Commun; 2018 Aug; 9(1):3049. PubMed ID: 30076299
[TBL] [Abstract][Full Text] [Related]
11. Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.
Munisvaradass R; Kumar S; Govindasamy C; Alnumair KS; Mok PL
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885562
[TBL] [Abstract][Full Text] [Related]
12. Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo.
Maldini CR; Claiborne DT; Okawa K; Chen T; Dopkin DL; Shan X; Power KA; Trifonova RT; Krupp K; Phelps M; Vrbanac VD; Tanno S; Bateson T; Leslie GJ; Hoxie JA; Boutwell CL; Riley JL; Allen TM
Nat Med; 2020 Nov; 26(11):1776-1787. PubMed ID: 32868878
[TBL] [Abstract][Full Text] [Related]
13. Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions.
Meng X; Jing R; Qian L; Zhou C; Sun J
Front Immunol; 2020; 11():1046. PubMed ID: 32636832
[TBL] [Abstract][Full Text] [Related]
14. Transient stimulation expands superior antitumor T cells for adoptive therapy.
Kagoya Y; Nakatsugawa M; Ochi T; Cen Y; Guo T; Anczurowski M; Saso K; Butler MO; Hirano N
JCI Insight; 2017 Jan; 2(2):e89580. PubMed ID: 28138559
[TBL] [Abstract][Full Text] [Related]
15. T cell stimulation and expansion by SunTag-based clustering of anti-CD3/CD28 scFv.
Zhong K; Liu Z; Li H; Zhao S; Wang Y; Guo W; Zheng X; Yang H; Guo G; Zhou L; Xu J; Tong A
Aging (Albany NY); 2020 Jun; 12(11):11061-11070. PubMed ID: 32526703
[TBL] [Abstract][Full Text] [Related]
16. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
17. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.
Stoiber S; Cadilha BL; Benmebarek MR; Lesch S; Endres S; Kobold S
Cells; 2019 May; 8(5):. PubMed ID: 31108883
[TBL] [Abstract][Full Text] [Related]
18. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
[TBL] [Abstract][Full Text] [Related]
19. Novel DNA-based T-Cell Activator Promotes Rapid T-Cell Activation and Expansion.
Keskar V; Sood A; Loghin E; Kovacs E; Duthie RS; Liu S; Park JH; Chadwick C; Smith R; Brown M; Stroncek DF; Highfill SL
J Immunother; 2020 Oct; 43(8):231-235. PubMed ID: 32796275
[TBL] [Abstract][Full Text] [Related]
20. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.
Kamiya T; Wong D; Png YT; Campana D
Blood Adv; 2018 Mar; 2(5):517-528. PubMed ID: 29507075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
